<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421316</url>
  </required_header>
  <id_info>
    <org_study_id>2011/504</org_study_id>
    <nct_id>NCT01421316</nct_id>
  </id_info>
  <brief_title>Hair-sparing Whole Brain Radiotherapy</brief_title>
  <official_title>Reducing Hair Loss With Volumetric Arc Therapy in Patients Treated With Whole Brain Radiotherapy: a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 10% of patients with cancer will develop symptomatic brain metastases. Given this&#xD;
      limited survival it is important to consider quality of life (QOL) when treating these&#xD;
      patients. Whole brain radiotherapy (WBRT) can increase survival to 6 month. However, WBRT&#xD;
      itself has been shown to reduce QOL by increasing drowsiness, leg weakness and hair loss in&#xD;
      patients with brain metastases. Both fatigue and hair loss were reported to have the largest&#xD;
      decline in QOL scores when WBRT is used in the prophylactic setting in small cell lung&#xD;
      cancer. Recent technological improvements in patient positioning and treatment planning will&#xD;
      allow us to treat the whole brain with reduced margins, allowing better sparing of the scalp.&#xD;
      In view of the large impact of hair loss on quality of life, the investigators hypothesize to&#xD;
      see an improved quality of life with scalp sparing techniques.&#xD;
&#xD;
      Study hypothesis: Volumetric arc therapy results in a reduced hair loss and a subsequent&#xD;
      clinically important improvement in QOL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No reduction in hair loss 1 month after treatment&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The European Organization for Research and Treatment of Cancer (EORTC)quality of life questionnaire (C15-PAL and BN20) measured at 1 month following treatment.</measure>
    <time_frame>At 1 month.</time_frame>
    <description>Quality of life questionnaires are used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hair quality before treatment and at 1 month following treatment.</measure>
    <time_frame>at 1 month following treatment</time_frame>
    <description>Key measurements: trichogram are used.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole brain radiotherapy with volumetric arc therapy</intervention_name>
    <description>Whole brain radiotherapy with volumetric arc therapy is used.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Recursive Partitioning Analysis (RPA) class III patients&#xD;
&#xD;
          -  Recursive Partitioning Analysis (RPA) class I-II patients and &gt;3 brain metastases&#xD;
&#xD;
          -  Patients with small cell lung cancer extended disease eligible for prophylactic&#xD;
             Whole-Brain Radiotherapy (WBRT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous whole brain radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ghent University Hospital, Belgium</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients treated with whole brain radiotherapy in the setting of brain metastases</keyword>
  <keyword>Patients treated with whole brain radiotherapy in the prophylactic treatment for small cell lung cancer (extended disease).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

